{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:45:27Z","timestamp":1794411927466,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41591-022-01937-6","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T16:02:46Z","timestamp":1660579366000},"page":"1619-1629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":250,"title":["Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-0398","authenticated-orcid":false,"given":"Christine D.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R.","family":"Rappaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan G.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran D.","family":"Scallan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue-Jean","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Gitlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren D.","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Kounlavouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Skoberne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8902-4305","authenticated-orcid":false,"given":"Kiara","family":"Taquechel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Marrali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Jaroslavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine N.","family":"Nganje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5023-8573","authenticated-orcid":false,"given":"Elizabeth","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Navarro-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne C.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijsbert","family":"Grotenbreg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2672-5136","authenticated-orcid":false,"given":"Wade","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Duc","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyounghwa","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameek","family":"Roychowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3002-1921","authenticated-orcid":false,"given":"David P.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Henick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Mahipal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8794-130X","authenticated-orcid":false,"given":"Steve B.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5356-0111","authenticated-orcid":false,"given":"Roman","family":"Yelensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel V. T.","family":"Catenacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jooss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"1937_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"1937_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"1937_CR3","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1937_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.it.2018.04.005","volume":"39","author":"CH Lee","year":"2018","unstructured":"Lee, C. H., Yelensky, R., Jooss, K. & Chan, T. A. Update on tumor neoantigens and their utility: why it is good to be different. Trends Immunol. 39, 536\u2013548 (2018).","journal-title":"Trends Immunol."},{"key":"1937_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ni.3682","volume":"18","author":"E Tran","year":"2017","unstructured":"Tran, E., Robbins, P. F. & Rosenberg, S. A. \u2018Final common pathway\u2019 of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 18, 255\u2013262 (2017).","journal-title":"Nat. Immunol."},{"key":"1937_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature10803","volume":"482","author":"M DuPage","year":"2012","unstructured":"DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405\u2013409 (2012).","journal-title":"Nature"},{"key":"1937_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577\u2013581 (2014).","journal-title":"Nature"},{"key":"1937_CR8","doi-asserted-by":"publisher","first-page":"16013","DOI":"10.1073\/pnas.0500090102","volume":"102","author":"V Lennerz","year":"2005","unstructured":"Lennerz, V. et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102, 16013\u201316018 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1937_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400\u2013404 (2012).","journal-title":"Nature"},{"key":"1937_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747\u2013752 (2013).","journal-title":"Nat. Med."},{"key":"1937_CR11","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"1937_CR12","doi-asserted-by":"publisher","first-page":"eaax7918","DOI":"10.1126\/scitranslmed.aax7918","volume":"11","author":"N McGranahan","year":"2019","unstructured":"McGranahan, N. & Swanton, C. Neoantigen quality, not quantity. Sci. Transl. Med. 11, eaax7918 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1937_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"1937_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"1937_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362.e324 (2020).","journal-title":"Cell"},{"key":"1937_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"1937_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107\u2013112 (2020).","journal-title":"Nature"},{"key":"1937_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019).","journal-title":"Nature"},{"key":"1937_CR19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949 e916 (2017).","journal-title":"Cell"},{"key":"1937_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.omtm.2019.11.001","volume":"15","author":"AR Shaw","year":"2019","unstructured":"Shaw, A. R. & Suzuki, M. Immunology of adenoviral vectors in cancer therapy. Mol. Ther. Methods Clin. Dev. 15, 418\u2013429 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1937_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04859-5","volume":"9","author":"C Lopez-Camacho","year":"2018","unstructured":"Lopez-Camacho, C. et al. Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat. Commun. 9, 2441 (2018).","journal-title":"Nat. Commun."},{"key":"1937_CR22","doi-asserted-by":"publisher","first-page":"286re285","DOI":"10.1126\/scitranslmed.aaa2373","volume":"7","author":"C Ogwang","year":"2015","unstructured":"Ogwang, C. et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci. Transl. Med. 7, 286re285 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1937_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial.Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"1937_CR24","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"& Sadoff, J. et al. Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine.N. Engl. J. Med. 384, 1824\u20131835 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1937_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fimmu.2018.00335","volume":"9","author":"H Zhao","year":"2018","unstructured":"Zhao, H. et al. Seroprevalence of neutralizing antibodies against human adenovirus type-5 and chimpanzee adenovirus type-68 in cancer patients. Front Immunol. 9, 335 (2018).","journal-title":"Front Immunol."},{"key":"1937_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/genes10030189","volume":"10","author":"K Lundstrom","year":"2019","unstructured":"Lundstrom, K. RNA viruses as tools in gene therapy and vaccine development. Genes (Basel) 10, 189 (2019).","journal-title":"Genes (Basel)"},{"key":"1937_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589\u2013593 (2020).","journal-title":"Nature"},{"key":"1937_CR28","doi-asserted-by":"publisher","first-page":"794528","DOI":"10.1155\/2015\/794528","volume":"2015","author":"MA McNamara","year":"2015","unstructured":"McNamara, M. A., Nair, S. K. & Holl, E. K. RNA-based vaccines in cancer immunotherapy. J. Immunol. Res 2015, 794528 (2015).","journal-title":"J. Immunol. Res"},{"key":"1937_CR29","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1128\/JVI.75.2.738-749.2001","volume":"75","author":"TM Allen","year":"2001","unstructured":"Allen, T. M. et al. CD8+ Lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class i molecule Mamu-A*01: implications for vaccine design and testing. J. Virol. 75, 738\u2013749 (2001).","journal-title":"J. Virol."},{"key":"1937_CR30","doi-asserted-by":"publisher","unstructured":"Bulik-Sullivan, B. et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat. Biotechnol., https:\/\/doi.org\/10.1038\/nbt.4313 (2018).","DOI":"10.1038\/nbt.4313"},{"key":"1937_CR31","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","volume":"6","author":"EX Chen","year":"2020","unstructured":"Chen, E. X. et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 Study. JAMA Oncol. 6, 831\u2013838 (2020).","journal-title":"JAMA Oncol."},{"key":"1937_CR32","doi-asserted-by":"publisher","first-page":"v123","DOI":"10.1093\/annonc\/mdy208.003","volume":"29","author":"J Bendell","year":"2018","unstructured":"Bendell, J. et al. Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab1cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Ann. Oncol. 29, v123 (2018). 2018.","journal-title":"Ann. Oncol."},{"key":"1937_CR33","doi-asserted-by":"publisher","first-page":"viii714","DOI":"10.1093\/annonc\/mdy424.020","volume":"29","author":"A Grothey","year":"2018","unstructured":"Grothey, A. et al. Fluoropyrimidine (FP) 1 bevacizumab (BEV) 1 atezolizumab vs FP\/BEV in BRAFwt metastatic colorectal cancer (mCRC): findings from cohort 2 of MODUL\u2013a multicentre, randomized trial of biomarkerdriven maintenance treatment following first-line induction therapy. Ann. Oncol. 29, viii714\u2013viii715 (2018).","journal-title":"Ann. Oncol."},{"key":"1937_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nri3567","volume":"14","author":"DL Farber","year":"2014","unstructured":"Farber, D. L., Yudanin, N. A. & Restifo, N. P. Human memory T cells: generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 14, 24\u201335 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"1937_CR35","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.4049\/jimmunol.1501721","volume":"196","author":"T Trolle","year":"2016","unstructured":"Trolle, T. et al. The length distribution of class I-restricted T cell epitopes is determined by both peptide supply and MHC allele-specific binding preference. J. Immunol. 196, 1480\u20131487 (2016).","journal-title":"J. Immunol."},{"key":"1937_CR36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","volume":"8","author":"M Wieczorek","year":"2017","unstructured":"Wieczorek, M. et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 8, 292 (2017).","journal-title":"Front Immunol."},{"key":"1937_CR37","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00262-014-1593-0","volume":"63","author":"L Chudley","year":"2014","unstructured":"Chudley, L. et al. Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol. Immunother. 63, 1199\u20131211 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"1937_CR38","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Disco. 10, 1842\u20131853 (2020).","journal-title":"Cancer Disco."},{"key":"1937_CR39","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259\u20131271 (2017).","journal-title":"Cell"},{"key":"1937_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479\u2013485 (2019).","journal-title":"Nature"},{"key":"1937_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06300-3","volume":"9","author":"KG Paulson","year":"2018","unstructured":"Paulson, K. G. et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat. Commun. 9, 3868 (2018).","journal-title":"Nat. Commun."},{"key":"1937_CR42","doi-asserted-by":"publisher","first-page":"CT002","DOI":"10.1158\/1538-7445.AM2021-CT002","volume":"18","author":"S Piperno-Neumann","year":"2021","unstructured":"Piperno-Neumann, S. et al. Phase 3 randomized trial comparing tebentafusp with investigator\u2019s choice in first line metastatic uveal melanoma.Cancer Res. 18, CT002 (2021).","journal-title":"Cancer Res."},{"key":"1937_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31005-z","volume":"13","author":"AR Rappaport","year":"2022","unstructured":"Rappaport, A. R. et al. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nat. Commun. 13, 3289 (2022).","journal-title":"Nat. Commun."},{"key":"1937_CR44","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","volume":"59","author":"Z Moodie","year":"2010","unstructured":"Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489\u20131501 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"1937_CR45","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/nprot.2015.068","volume":"10","author":"S Janetzki","year":"2015","unstructured":"Janetzki, S. et al. Guidelines for the automated evaluation of Elispot assays. Nat. Protoc. 10, 1098\u20131115 (2015).","journal-title":"Nat. Protoc."},{"key":"1937_CR46","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1200\/JCO.2012.45.7903","volume":"31","author":"Y Ji","year":"2013","unstructured":"Ji, Y. & Wang, S. J. Modified toxicity probability interval design: a safer and more reliable method than the 3\u2009+\u20093 design for practical phase I trials. J. Clin. Oncol. 31, 1785\u20131791 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1937_CR47","first-page":"51","volume":"302","author":"S Janetzki","year":"2005","unstructured":"Janetzki, S., Cox, J. H., Oden, N. & Ferrari, G. Standardization and validation issues of the ELISPOT assay. Methods Mol. Biol. 302, 51\u201386 (2005).","journal-title":"Methods Mol. Biol."},{"key":"1937_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","volume":"79","author":"M Roederer","year":"2011","unstructured":"Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytom. A 79, 167\u2013174 (2011).","journal-title":"Cytom. A"},{"key":"1937_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"1937_CR50","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1937_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9, 34 (2017).","journal-title":"Genome Med"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01937-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01937-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01937-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T10:05:56Z","timestamp":1660817156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01937-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1937"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01937-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"4 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.D.P., A.R.R., M.G.H., C.D.S., L.G., S-.J.H., L.D.K., S.K., D.S., M.D., M.M., J.R.J., C.N.N., R.Z., D.N.G., A.C.G., M.D.C., S.C., K.B., R.R., A.A., A.R.F., K.J., A.Y., L.S., M.S., K.T., E.M., G.G., R.G., W.B. and R.Y. are stockholders and either current or previous employees at Gritstone bio and may be listed as co-inventors on various pending patent applications related to the vaccine platform presented in this study. D.V.T.C. consults\/has consulted\/has advisory\/had advisory roles at Genentech\/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone bio, Pieris, Zymeworks, Basilea, QED, Foundation Medicine, Pierian, Silverback Therapeutics, Servier, Blueprint Medicines, Arcus Biosciences, Tempus, Guardant Health, Archer and Natera. C.G.D. is currently employed by Janssen R&D. B.S.H. has\/had consultant\/advisory roles for AstraZeneca, Ideaya, Jazz Pharmaceuticals, and research support from Neximmune. B.J.S. consults\/has consulted\/had advisory roles for Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Pfizer, Roche\/Genentech, Amgen, Lilly, Sanofi-Regeneron, Glaxo-Smith Kline, Takeda, Novartis and Beigene; has received honoria from Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Pfizer, Roche\/Genentech, Amgen, Lilly, Sanofi-Regeneron, Glaxo-Smith Kline, Takeda, Novartis and Beigene; has received research funding from Sanofi-Regeneron; and has received royalties from UpToDate. B.J. consulted for\/had advisory roles with Taiho Oncology, Insmed Oncology, Gritstone bio, Pfizer and Incyte and received research funding from Gateway for Cancer Research, Bristol Myers Squibb and Syntrix. A.M. is on the Advisory Board for AstraZeneca, QED, and Taiho Oncology. S.R. participated in Advisory Boards for Incyte Corporation (2017), AbbVie (2017), QED Therapeutics (2018, 2019) and Bayer (2020) (healthcare companies <10,000 USD). S.R. received honoraria from IDT (2017) and Illumina (2018) (technology companies). S.R. received consulting fees from QED Therapeutics (2018, 2019) and Merck (2019) (healthcare companies <10,000 USD). S.R. received travel reimbursement from Incyte Corporation (2019) (<999 USD). C.Y.L. received honoraria from Cancer Experts Now and has consulting\/advisory board roles with Transthera, BluePrints Medicine, Genentech, QED Therapeutics, Histosonics and Ipsen and is part of the Speaker\u2019s Bureau for Eisai and Incyte. S.B.M. received honoraria from Natera, Bicara, Novartis, Basilea and Daiichi Sankyo and owned stock in Calithera outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}